TP53 and breast cancer: Many cell cycle components contribute to a more aggressive tumor phenotype and poorer prognosis among Black breast cancer patients (38), such as higher mitotic index; overexpression of cyclin E, p16, p53; and lower expression of cyclin D1 (39).